Cleveland Diagnostics is a diagnostics company developing efficacious, affordable diagnostics tests to improve cancer diagnostics.
Cleveland Diagnostics is a commercial-stage diagnostics company developing efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. Its solvent interaction analysis technology investigates protein biomarkers at the structural level, providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process. Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to breast cancer and lung cancer, and certain neurological diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 9, 2021 | Convertable Note | $2M | — | — | — | Detail |
Feb 9, 2021 | Series D | $17.40M | 2 | LYFE Capital | — | Detail |
Nov 28, 2017 | Convertable Note | $2M | 1 | Genomic Health | — | Detail |
Dec 12, 2016 | Series B | $5M | — | — | — | Detail |
Jan 18, 2016 | Series C | $7.60M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
LYFE Capital | Yes | Series D |
Genomic Health | Yes | Convertable Note |
Cleveland Clinic | — | Series D |